Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide in steroid-refractory GI acute GVHD
NCT05415410Phase 2Terminated
- Sponsor
- VectivBio
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of apraglutide in Acute Graft-Versus-Host Disease (aGvHD), sponsored by VectivBio. Started May 2022; status: terminated.
02
Drugs
apraglutide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05415410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415410.